Preclinical program CS585 can be described as small molecules, analogs to the endogenous metabolite 12-HETrE. It is a stable, selective, and potent IP (prostacyclin) receptor agonist that has demonstrated potential to significantly improve on mechanism relevant to selected cardiovascular diseases through initial in vivo animal models.
CS585 is now undergoing a preclinical development program through a research collaboration with the University of Michigan.
The preclinical program CS014 is being developed for the treatment of cardiovascular diseases. A preclinical development program is now being conducted with CS014 in collaboration with the University of Michigan.
CS014 was acquired from Emeriti Bio in March 2019 and has since been developed in a collaboration between Cereno and Emeriti Bio.